Ibrutinib in patients with relapsed/refractory central nervous system lymphoma: A retrospective single-centre analysis

Br J Haematol. 2020 Jul;190(2):e110-e114. doi: 10.1111/bjh.16759. Epub 2020 May 26.

Eliza M Lauer¹, Miguel Waterhouse¹, Moritz Braig², Jurik Mutter¹, Sabine Bleul¹, Jesús Duque-Afonso¹, Justus Duyster^{1

3}, Reinhard Marks¹, Peter C Reinacher^{4

5}, Marco Prinz^{6

7

8}, Gerald Illerhaus⁹, Jürgen Finke¹, Elisabeth Schorb¹, Florian Scherer^{1

3}

¹ Department of Medicine I, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
² Department of Radiology, Medical Physics, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
³ German Cancer Consortium (DKTK) partner site Freiburg and German Cancer Research Center (DKFZ), Heidelberg, Germany.
⁴ Department of Stereotactic and Functional Neurosurgery, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
⁵ Fraunhofer Institute for Laser Technology, Aachen, Germany.
⁶ Institute of Neuropathology, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
⁷ Center for Basics in NeuroModulation (NeuroModulBasics), Faculty of Medicine, University of Freiburg, Freiburg, Germany.
⁸ Signaling Research Centres BIOSS and CIBSS, University of Freiburg, Freiburg, Germany.
⁹ Department of Hematology/Oncology and Palliative Care, Stuttgart, Germany.

No abstract available

Keywords: BTK inhibition; Ibrutinib; central nervous system lymphoma; real-world analysis; relapsed/refractory disease.

Publication types